close
Vector-Based Gene Therapy and Gene-Editing Products – Ongoing Clinical Trials
News

Vector-Based Gene Therapy and Gene-Editing Products – Ongoing Clinical Trials

Vector-Based Gene Therapy and Gene-Editing Products
Ongoing Clinical Trials

Gene therapies are now a reality. They open new perspectives for the treatment and management of a wide range of rare and common diseases. We have listed ongoing clinical trials using viral vector and gene editing products to get a more accurate understanding of their clinical trends and take account of integrate their growth potential. The scope of our up-dated booklet is to provide an overview of key figures for the most advanced vector-based gene therapy products (main therapeutic areas, geographical distribution of sponsors, geographical distribution of trials, type of vectors used by therapeutic area, type of vectors used ….).

211 Ongoing Trials in More than 10 Therapeutic Areas
106 Sponsors from 13 Countries Have Initiated These 211 Ongoing Trials
68 % of Ongoing Trials with At Least One Location in the USA
72 % of Ongoing Trials with At Least One Location in Europe
AAV-Based Vectors and Lentiviral Vectors are The Most Widely Used Vectors
72 % of Ongoing Trials are Early-Phase Trials (I or I-II)
Hematological Diseases and Ophthalmological Diseases Are The Most Advanced Therapeutic Areas

Click  to download the complete study (11 pages):  Vector-Based Gene Therapy and Gene-Editing Products

This study is based on data extracted from Clinicaltrials.gov. Selected trials have been registered and/or updated until 11/07/2020. Trials have been choosen on the basis of the following criteria:
• Interventional studies containing the term “gene therapy”
• Recruitment status (Not yet recruiting – Recruiting – Enrolling by invitation – Active, not recruiting).
CAR-T cells and oncolytic viruses have been excluded.


COMMENTS ARE OFF THIS POST